ICH guideline M10 on BA method validation [Regulatives / Guidelines]

posted by PSU – Thailand, 2022-05-03 17:53 (1516 d 12:45 ago) – Posting: # 22956
Views: 4,691

Dear all experts,

Referring to ICH guideline M10 on BA method validation step2b (line no.413-414, p.11), CC and QCs should be prepared from separate stock solution in order to avoid biased estimations which are not related to the analytical performance of the method.

Can you explain how separate stock solution can avoid biased estimations? and what are the bias estimations that happen regarding this sentence, if we use the same stock solution ?

Thank you so much

PSU

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,572 registered users;
355 visitors (0 registered, 355 guests [including 36 identified bots]).
Forum time: 06:38 CEST (Europe/Vienna)

The real struggle is not between the right and the left
but between the party of the thoughtful
and the party of the jerks.    Jimmy Wales

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5